Description of the blood test:

Anti-Scl-70 antibodies target an enzyme called Topoisomerase I, which is essential for “unwinding” DNA during replication and transcription. When the immune system produces antibodies against this enzyme, it is highly characteristic of Systemic Sclerosis (Scleroderma), specifically the diffuse cutaneous form. This condition is characterized by the overproduction of collagen, leading to the thickening and hardening of the skin and potential scarring of internal organs like the lungs and heart.

What Does the Test Represent?

• Goal: To detect and measure IgG antibodies against the Scl-70 (Topoisomerase I) antigen.
• Main Application: Diagnosing Systemic Sclerosis and predicting the risk of extensive skin involvement and Interstitial Lung Disease (ILD).
• Method: Enzyme-Linked Immunosorbent Assay (ELISA) or Immunoblot.

Collection Recommendations (General)

• Timing: Morning collection is standard.
• Fasting: Fasting for 8–12 hours is recommended; plain water is allowed.
• Material: Venous blood (serum).
• Specific Rules: Inform your doctor if you have noticed any skin tightening on your chest, arms, or thighs, or if you experience significant shortness of breath.

Factors Influencing the Result

• Disease Subtype: These antibodies are found in about 20–40% of all Scleroderma patients but are almost exclusively found in the diffuse form, which progresses faster than the limited form.
• Prognostic Value: The presence of Anti-Scl-70 is a strong predictor of Interstitial Lung Disease (ILD), meaning the lungs may develop fibrosis (scarring).
• Specificity: Like Anti-Sm in Lupus, Anti-Scl-70 is highly specific (nearly 100%)—it is almost never found in healthy individuals.

When to Take This Test?

• Recommendations: If you have skin that feels tight, thick, or hard (especially on the trunk or upper arms); severe Raynaud’s phenomenon (fingers turning white/blue in cold); or unexplained scarring on lung X-rays.
• Importance: Early identification helps doctors monitor the lungs more aggressively, as early treatment can help preserve lung function.

Medical Interpretation

• Crucial Note: While a positive result is very specific for Scleroderma, it doesn’t tell you how fast the disease will progress. Only a specialist can “fine-tune” the treatment by performing regular lung function tests and skin scoring.
• Positive Result: Highly indicative of Diffuse Systemic Sclerosis and an increased risk of lung fibrosis.
• Negative Result: Does not rule out Scleroderma. Many patients with the “Limited” form will instead test positive for Centromere Antibodies.

Possible Further Investigations

• Nailfold Capillaroscopy: To look for damaged microscopic blood vessels (common in Scleroderma).
• High-Resolution CT (HRCT) of the Lungs: To check for early signs of interstitial lung disease.
• Pulmonary Function Tests (PFTs): To measure how well the lungs are moving oxygen into the blood.
• Echocardiogram: To screen for pulmonary arterial hypertension.
• Consultation with a Rheumatologist.

When Does the Next Step Make Sense?

• If the Anti-Scl-70 test is positive, the most important next step is a baseline evaluation of the lungs (CT scan and PFTs), even if you don’t feel short of breath. Early intervention is the key to managing internal organ involvement in Scleroderma.
• All clinical decisions must be made by a healthcare professional based on the physical examination of the skin and internal organ screening.

👉 If necessary, you can discuss the analysis results with a specialist such as a rheumatologist (Doctors – TAMC).